Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aduro BioTech Inc    ADRO

ADURO BIOTECH INC

(ADRO)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Aduro Biotech: 2Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/02/2019 | 05:09am EDT

BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Thursday reported a loss of $18.6 million in its second quarter.

On a per-share basis, the Berkeley, California-based company said it had a loss of 23 cents.

The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share.

The drug developer posted revenue of $4.9 million in the period, topping Street forecasts. Four analysts surveyed by Zacks expected $4.6 million.

The company's shares closed at $1.40. A year ago, they were trading at $5.40.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ADRO at https://www.zacks.com/ap/ADRO

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ADURO BIOTECH INC
08/02ADURO BIOTECH : 2Q Earnings Snapshot
AQ
08/01ADURO BIOTECH, INC. : Results of Operations and Financial Condition, Financial S..
AQ
08/01ADURO BIOTECH : Management's Discussion and Analysis of Financial Condition and ..
AQ
08/01Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financ..
GL
07/02ADURO BIOTECH, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/03ADURO BIOTECH : Fell 40% on Monday Following Study Results, Downgrade
DJ
06/02Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STI..
GL
06/02ADURO BIOTECH : and Novartis Present Results from Ongoing Phase 1b Study of STIN..
AQ
05/29ADURO BIOTECH : CFO Sells 18,602 Shares of Stock
AQ
05/16ADURO BIOTECH : to Host Investor Event Featuring ADU-S100 Clinical Data Presente..
AQ
More news
Financials (USD)
Sales 2019 18,9 M
EBIT 2019 -82,7 M
Net income 2019 -77,2 M
Finance 2019 223 M
Yield 2019 -
P/E ratio 2019 -1,42x
P/E ratio 2020 -1,68x
EV / Sales2019 -6,00x
EV / Sales2020 -2,95x
Capitalization 109 M
Chart ADURO BIOTECH INC
Duration : Period :
Aduro BioTech Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADURO BIOTECH INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 5,88  $
Last Close Price 1,36  $
Spread / Highest target 635%
Spread / Average Target 332%
Spread / Lowest Target 10,3%
EPS Revisions
Managers
NameTitle
Stephen T. Isaacs Chairman, President & Chief Executive Officer
Jennifer Lew Chief Financial Officer
Andrea van Elsas Chief Scientific Officer
Ross Haghighat Independent Director
William Mariner Greenman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ADURO BIOTECH INC-48.48%109
GILEAD SCIENCES1.42%81 192
VERTEX PHARMACEUTICALS10.87%48 089
REGENERON PHARMACEUTICALS-20.74%32 649
GENMAB26.56%13 270
NEUROCRINE BIOSCIENCES, INC.35.88%9 041